Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + CDK4/6 inhibitor + endocrine therapy for first-line advanced HR-positive/HER2-negative breast cancer
ChiCTR2600132757Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600132757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132757.